GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 50 to 59 ...

That's why the American Lung Association, with support from GlaxoSmithKline, is encouraging adults at ... If you have already received an RSV vaccine, you do not need another one. Talk with your ...

AIM Vaccine will rapidly advance the clinical trials of the mRNA respiratory syncytial virus (RSV) vaccine. As a new and globally heavyweight key vaccine product, this product is expected to become a ...

The U.S. Food and Drug Administration approved Moderna's RSV vaccine in May. Blake Brittain reports on intellectual property law, including patents, trademarks, copyrights and trade secrets ...

(Reuters) -British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology with its blockbuster ...

British drugmaker GlaxoSmithKline sued Moderna in US federal ... The US Food and Drug Administration approved Moderna's RSV vaccine in May. GSK said in the new cases that its patents cover ...

(Reuters) -British drugmaker GlaxoSmithKline (NYSE ... in messenger RNA technology with its blockbuster COVID-19 vaccine Spikevax and RSV shot mResvia. According to the two lawsuits, Moderna's ...